Hexagon Nutrition Ltd
Incorporated in 1993, Hexagon Nutrition
Ltd is a research-driven nutrition company.[1]
- Market Cap ₹ 725 Cr.
- Current Price ₹ 59.0
- High / Low ₹ 78.7 / 48.0
- Stock P/E 16.6
- Book Value ₹ 20.0
- Dividend Yield 0.52 %
- ROCE 22.2 %
- ROE 17.3 %
- Face Value ₹ 1.00
Pros
- Company has delivered good profit growth of 51.2% CAGR over last 5 years
Cons
- Working capital days have increased from 105 days to 168 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|
| 99 | 86 | 107 | 114 | 132 | 267 | 316 | 386 | |
| Sales growth | -13% | +24% | +7% | +16% | +102% | +19% | ||
| 88 | 79 | 94 | 115 | 119 | 233 | 273 | 335 | |
| Operating Profit | 10 | 7 | 13 | -1 | 13 | 34 | 43 | 51 |
| OPM % | 11% | 9% | 12% | -0.8% | 10% | 13% | 14% | 13% |
| 1 | 3 | 2 | 2 | 5 | 10 | 16 | 15 | |
| Interest | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 |
| Depreciation | 3 | 2 | 2 | 3 | 3 | 5 | 6 | 6 |
| Profit before tax | 8 | 7 | 13 | -3 | 14 | 36 | 51 | 58 |
| Tax % | 7% | 24% | 29% | 18% | 25% | 26% | 26% | |
| 7 | 6 | 9 | -3 | 10 | 27 | 38 | 43 | |
| EPS in Rs | 0.60 | 0.46 | 0.73 | -0.25 | 0.85 | 2.19 | 3.10 | 3.51 |
| Dividend Payout % | -0% | -0% | -0% | -0% | -0% | -0% | -0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 30% |
| 3 Years: | 41% |
| TTM: | 19% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 51% |
| 3 Years: | 269% |
| TTM: | 41% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 15% |
| 3 Years: | 18% |
| Last Year: | 17% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 12 |
| Reserves | 35 | 37 | 56 | 51 | 61 | 181 | 220 | 234 |
| 26 | 25 | 22 | 28 | 40 | 12 | 25 | 24 | |
| 24 | 21 | 26 | 36 | 28 | 36 | 49 | 69 | |
| Total Liabilities | 96 | 94 | 116 | 126 | 141 | 241 | 305 | 339 |
| 21 | 20 | 20 | 22 | 25 | 40 | 41 | 39 | |
| CWIP | 0 | 0 | 2 | 1 | 2 | 1 | 1 | 2 |
| Investments | 12 | 16 | 20 | 16 | 8 | 32 | 34 | 24 |
| 62 | 58 | 74 | 86 | 107 | 168 | 230 | 274 | |
| Total Assets | 96 | 94 | 116 | 126 | 141 | 241 | 305 | 339 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| 10 | 5 | 1 | 7 | -2 | 21 | 8 | |
| -1 | -2 | -11 | -8 | -8 | -5 | -20 | |
| -5 | -4 | 7 | 3 | 11 | -20 | 11 | |
| Net Cash Flow | 5 | -1 | -3 | 2 | 1 | -3 | -1 |
| Free Cash Flow | 9 | 5 | -4 | 2 | -8 | 16 | 3 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 113% | 75% | 31% | -852% | 5% | 91% | 45% |
Ratios
Standalone / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 50 | 57 | 52 | 76 | 67 | 81 | 90 |
| Inventory Days | 128 | 149 | 192 | 150 | 146 | 132 | 145 |
| Days Payable | 108 | 95 | 108 | 152 | 80 | 48 | 61 |
| Cash Conversion Cycle | 71 | 110 | 136 | 74 | 132 | 164 | 174 |
| Working Capital Days | 89 | 58 | 76 | 65 | 1 | 147 | 168 |
| ROCE % | 10% | 15% | 2% | 15% | 23% | 22% |
Insights
In beta| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Capacity Utilization - Clinical Nutrition % |
|
||||||
| Export Revenue Share (Rest of World) % of revenue |
|||||||
| Top 10 Customer Revenue Concentration % of revenue |
|||||||
| Branded Nutrition Segment Revenue Share % of revenue |
|||||||
| Number of Distributors count |
|||||||
| Number of Permanent Employees (Consolidated) count |
|||||||
| Production Volume - Dry Pre-mix MT |
|||||||
| Production Volume - Ready-to-Use Food (RUF/RUTF) MT |
|||||||
| Capacity Utilization - Blended (All Products) % |
|||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
- Audio recording of 17 Nov 2026 earnings call for Q2/H1 FY27 results is now available.
-
Announcement under Regulation 30 (LODR)-Investor Presentation
- Hexagon Nutrition Limited has informed about Investor presentation
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
- Hexagon Nutrition announced H1 FY27 revenue of ₹214.0 crore and PAT of ₹16.2 crore.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Hexagon Nutrition Limited has informed about copy of Newspaper Publication-Q2 Results.
-
Financial Results For The Quarter And Half Year Ended September 30, 2026
- Board approved Q2/H1 FY27 results and began phased Nashik premix facility decommissioning.
Concalls
-
Nov 2026PPT REC
-
Aug 2026Transcript PPT REC
-
Jul 2026Transcript PPT REC
Business Profile:[1]
Hexagon Nutrition is a research-
driven nutrition company engaged
in the development, manufacturing
and marketing of nutrition products
across micronutrient premixes, branded
wellness and clinical nutrition, therapeutic formulations, ready-to-use foods (RUFs)
and micronutrient powders (MNPs).